All In Biotech

Drug Trial Radar · NCT06100744

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

Open-label, Randomized, Assessor-blinded, Efficacy, Safety, Tolerability, and Pharmacokinetics Study of Subcutaneous Risankizumab With an Adalimumab Reference Arm in Children With Active Juvenile Psoriatic Arthritis

Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jul 8, 2024

Primary completion

Sep 2026

Study completion Oct 2028

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Oct 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. PsA that begins before a patient's 16th birthday is called juvenile PsA (jPsA).This study will evaluate how safe risankizumab is for the treatment of psoriatic arthritis and to assess change in disease symptoms. Risankizumab is being studied for the treatment of jPsA and adalimumab is approved for the treatment of jPsA. Participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 4 chance that participants will be assigned to receive adalimumab. Approximately 40 juvenile participants with jPsA will be enrolled at approximately 30 sites worldwide. Participants will receive risankizumab and adalimumab as subcutaneous (SC) injections based on body weight. At the start of Period 1, participants are randomized to receive risankizumab or adalimumab for 24 weeks. Participants who respond to the study treatment received in Period 1, will continue to receive the same treatment in Period 2 for another 100 weeks. Those with worsening jPsA symptoms in Period 2 will be withdrawn from the study. Participants who receive adalimumab are followed for safety for 70 days after the last study treatment. Participants who receive risankizumab are followed for 140 days after the last study treatment. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Juvenile Psoriatic Arthritis

Interventions

  • AdalimumabDrug

    SC Injection

  • RisankizumabDrug

    Subcutaneous (SC) Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants who Achieve >= 30% Improvement in Juvenile Idiopathic Arthritis American College of Rheumatology Response Criteria (JIA-ACR 30)Time frame: Up to 24 Weeks
  2. Number of Participants with Adverse Events (AEs)Time frame: Up to Week 144

Locations

34 sites in 9 countries. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital /ID# 258776

    Little Rock, Arkansas · Recruiting

  • Childrens National Medical Center /ID# 259284

    Washington D.C., District of Columbia · Recruiting

  • Joe Dimaggio Children's Hospital Hollywood /ID# 260634

    Hollywood, Florida · Recruiting

  • All X Ray Diagnostic Services Corp /ID# 278523

    Miami, Florida · Recruiting

  • Indiana University Health Riley Hospital for Children /ID# 259067

    Indianapolis, Indiana · Recruiting

  • M Health Fairview University of Minnesota Medical Center - West Bank /ID# 260111

    Minneapolis, Minnesota · Recruiting

  • Columbia University Medical Center /ID# 262587

    New York, New York · Recruiting

  • Boston Childrens Health Physicians /ID# 258061

    Valhalla, New York · Recruiting

  • University of North Carolina - Children's Hospital /ID# 259286

    Chapel Hill, North Carolina · Recruiting

  • MetroHealth Medical Center /ID# 262377

    Cleveland, Ohio · Recruiting

  • Cleveland Clinic - Cleveland /ID# 276655

    Cleveland, Ohio · Recruiting

  • Child Neurology Consultants of Austin /ID# 260562

    Austin, Texas · Recruiting

  • Monash Health - Monash Medical Centre - Clayton /ID# 260255

    Clayton, Victoria, Australia · Recruiting

  • Alberta Children's Hospital /ID# 257880

    Calgary, Alberta, Canada · Recruiting

  • British Columbia Children and Women's Hospital and Health Centre /ID# 257884

    Vancouver, British Columbia, Canada · Recruiting

  • Hospital for Sick Children /ID# 257879

    Toronto, Ontario, Canada · Recruiting

  • Chu Bordeaux - Hopital Pellegrin /ID# 258729

    Bordeaux, New Aquitaine, France · Recruiting

  • AP-HP - Hopital Bicetre /ID# 258728

    Le Kremlin-Bicêtre, Paris, France · Recruiting

  • Helios Klinikum Berlin - Buch /ID# 268803

    Berlin, Germany · Recruiting

  • Hamburger Zentrum fuer Kinder- und Jugendrheumatologie /ID# 259104

    Hamburg, Germany · Recruiting

  • Asklepios Klinik Sankt Augustin /ID# 259106

    Sankt Augustin, North Rhine-Westphalia, Germany · Recruiting

  • Azienda Ospedaliero Universitaria Meyer /ID# 258587

    Florence, Firenze, Italy · Recruiting

  • ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO /ID# 276753

    Milan, Milano, Italy · Recruiting

  • Ospedale Pediatrico Bambino Gesu /ID# 258869

    Rome, Roma, Italy · Recruiting

  • Malopolskie Badania Kliniczne /ID# 258777

    Cracow, Lesser Poland Voivodeship, Poland · Recruiting

  • SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi /ID# 258785

    Lodz, Łódź Voivodeship, Poland · Recruiting

  • Uniwersytecki Szpital Dzieciecy w Lublinie /ID# 258781

    Lublin, Lublin Voivodeship, Poland · Recruiting

  • Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji im. prof. dr hab. med. /ID# 277050

    Warsaw, Masovian Voivodeship, Poland · Recruiting

  • Centrum Zdrowia Dziecka i Rodziny im Jana Pawla II w Sosnowcu /ID# 277058

    Sosnowiec, Silesian Voivodeship, Poland · Recruiting

  • Hospital Universitario y Politecnico La Fe /ID# 257567

    Valencia, Spain · Recruiting

  • Hospital Sant Joan de Deu /ID# 257568

    Esplugues de Llobregat, Barcelona, Spain · Recruiting

  • University Hospitals Bristol and Weston NHS Foundation Trust /ID# 258847

    Bristol, United Kingdom · Recruiting

  • Alder Hey Children's NHS Foundation Trust /ID# 262770

    Liverpool, United Kingdom · Recruiting

  • Sheffield Children's Hospital NHS Foundation Trust /ID# 258848

    Sheffield, England, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.